Supplementary results focusing on the end-of-intervention timepoint

Primary outcomes

At 6-month follow-up, the intervention group showed a larger change in SCI score (M = 4.89, SD = 6.02) than the control group (M = 2.05, SD = 6.80), with an effect size of d = 0.44. This difference was statistically significant, t (106) = 2.23, p = .027. When only participants that did not meet the threshold for insomnia at baseline were considered (n = 71) a similar effect size was found d = 0.55. The effect size was smaller for participants who did meet the insomnia threshold at baseline (d = 0.22) (n = 35).

A total of 67% of participants in the intervention group had a change score above the mean of the control group (Cohen's U₃). There was an overlap of 82%, and the probability that a person picked at random from the intervention group had a higher score than a person picked at random from the control group was 62%.

Within the intervention group, there was a significant reduction (by 21%) in the number of participants who met insomnia disorder threshold score at the 6-month follow up assessment, compared to baseline (baseline = 36%, 6-month follow-up= 15%), $\chi^2(1) = 8.65$, p = .003. In the control group, there was a non-significant 7% reduction (baseline = 28%, 6-month follow-up = 20%), $\chi^2(1) = 1.00$, p = .317. A total of 33% of participants in the intervention group met or exceeded the RCI of 7, and 27% of participants in the control group met or exceeded the RCI of 7 ($\chi^2(1) = 0.60$, p = .439).

A generalized estimating equation predicting change in SCI score from group, time, and the group x time interaction (with baseline SCI and age as covariates) showed a significant effect of group, with a larger change in SCI score in the intervention group compared to the control group ($\beta = 1.88, 95\%$ CI = 0.34 - 3.41, p = .017).

Secondary and exploratory outcomes

A set of generalizing estimating equations were performed to examine changes in associated variables across the course of the study. For these analyses, 6-month follow-up was added as an additional time point. Coefficients and 95% CI for the effect of group on change in

insomnia symptoms are shown in **Figure S1A**. Anxiety symptoms ($\beta = -2.56, 95 \%$ CI = -4.91 – -0.22, p = .032), experience of hallucinations ($\beta = -1.14, 95\%$ CI = -2.11 – -0.16, p = .022), and perceived stress ($\beta = -2.07, 95\%$ CI = -3.88 – -0.26, p = .025) were all reduced in the intervention group compared to the control.

Group * moderator interactions are shown in **Figure S1B**. Baseline anxiety symptoms showed the largest co-efficient size ($\beta = 0.73$, 95% CI = 0.10 – 1.55). The combined moderator (a composite of all other moderators, based on the method of Kraemer, 2013) was the only term where the confidence intervals did not cross 0.

Mediated regressions were run to examine whether group membership predicting insomnia symptoms at the 6-month follow-up were mediated by other sleep-related variables (**Figure S1C**). Only dysfunctional beliefs about sleep showed clear evidence of an indirect effect ($\beta = 1.11, 95\%$ CI = 0.20 - 2.02)

		Scale reliabilities (a)					
Measure	Baseline	Mid-	End of	6-month			
Wiedsule	Dasenne	intervention	intervention	follow-up			
Demographics	N/A	N/A	N/A	N/A			
SCI	.85	.88	.89	.86			
STAI	.92	.93	.94	.93			
MFQ	.91	.94	.91	.93			
ADHD	.92	-	.93	.94			
SPEQP	.91	-	.92	.91			
SPEQH	.79	-	.89	.88			
SPEQC	.63	-	.73	.82			
PMH	.94	.95	.95	.95			
PSS	.84	.90	.88	.90			
LTE	.70	.61	.63	.63			
PSQI	.69	.63	.64	.69			
PSQIA	.69	-	.72	.76			
PSASS	.82	.87	.82	.90			
PSASC	.89	.92	.91	.92			
DBAS	.78	.82	.88	.84			
MCTQ	N/A	-	N/A	N/A			
TAQ		.61	.73				

Supplementary Table 1. Scale reliabilities

Note. α = Cronbach's alpha

SCI = Sleep condition indicator; STAI = State trait anxiety index (trait); MFQ = Mood and feelings questionnaire; ADHD = Attention deficit hyperactivity disorder symptoms; SPEQP =Specific psychotic experiences questionnaire paranoia subscale; SPEQH = Specific psychotic experiences questionnaire hallucinations subscale; SPEQC = Specific psychotic experiences questionnaire cognitive disorganization subscale; PMH = Positive mental health scale; PSS =Perceived stress scale; LTE = List of threatening events; PSQI = Pittsburgh sleep quality index, PSQIA = Pittsburgh sleep quality index addendum; PSASS = Pre-sleep arousal scale somatic subscale; PSASC = Pre-sleep arousal scale cognitive subscale; DBAS = Dysfunctional beliefsabout sleep questionnaire; MCTQ = Munich chronotype questionnaire; TAQ = Treatmentacceptability questionnaire

Predictor	β	95% CI	p-value
[DV: SCI score over time]			
Group [reference: Control]			
Intervention	1.94	0.42 - 3.47	.013
Time [reference: Mid-intervention)			
End of intervention	1.61	0.40 - 2.82	.009
Group x time interaction			
Intervention x end of intervention	0.18	-1.54 - 1.90	.838
<u>Co-variates</u>			
Baseline SCI score	5.18	4.48 - 5.87	<.001
Age	-0.01	-0.22 - 0.20	.903
0	e interv	als. SCI = Slee	ep condition indica
<i>Note</i> . β = Co-efficient, CI = Confidenc			

Supplementary Table 2. Generalized estimating equation assessing change in SCI score over time

For the effect of group, the co-efficient indicates change in SCI score across time in the intervention group *compared* to the control group. For the effect of time, co-efficients indicate change in SCI score at end of intervention and 6-month follow *compared* to the mid-intervention. For the group x time interaction, the control group and mid-intervention time points are used as the references.

Predictor variables	Model information			
Anxiety symptoms				
DV: Anxiety symptoms				
	β	95% CI	p-value	
Group [reference: Control]				
Intervention	-2.58	-4.900.25	.030	
Time [reference: Mid-intervention)				
End of intervention	-1.74	-3.100.39	.012	
Group x time interaction	o 1 -			
Intervention x end of intervention	-0.47	-2.57 – 1.62	.658	
<u>Co-variates</u>				
Baseline insomnia symptoms	-0.87		.152	
Baseline anxiety symptoms	7.76		<.001	
Age	-0.27	-0.57 - 0.03	.077	
Depression symptoms				
DV: Depression symptoms				
	β	95% CI	p-value	
Group [reference: Control]	•		1	
Intervention	-0.63	-2.24 - 1.01	.456	
Time [reference: Mid-intervention)				
End of intervention	-1.83	-2.990.68	.002	
Group x time interaction				
Intervention x end of intervention	-0.09	-1.79 – 1.62	.920	
<u>Co-variates</u>				
Baseline insomnia symptoms	-0.95	-1.740.17	.017	
Baseline depression symptoms	3.83	3.06 - 4.59	<.001	
Age	-0.18	-0.31005	.006	
ADHD symptoms				
DV: ADHD symptoms				
	β	95% CI	p-value	
Group [reference: Control] Intervention	-2.34	-5.21 - 0.53	.110	
mervention	-2.34	5.21 - 0.55	.110	
<u>Co-variates</u>				
Baseline insomnia symptoms	-1.27		.135	
Baseline ADHD symptoms		6.62 - 9.66	<.001	
Age	-0.23	-0.49 - 0.02	.073	

Supplementary Table 3. Generalized estimating equation models for changes in variables across the intervention

Psychotic experiences – Paranoia

DV: Experiences of paranoia	β	95% CI	n voluo
Group [reference: Control]	р	95% CI	p-value
Intervention	-1.69	-3.310.07	.041
Co-variates			
Baseline insomnia symptoms	-0.92	-1.95 - 0.12	.082
Baseline experiences of paranoia	2.86	1.93 - 3.80	<.001
Age	-0.14	-0.35 - 0.06	.183
Psychotic experiences – Hallucinations			
DV: Experiences of hallucinations			
	β	95% CI	p-value
Group [reference: Control] Intervention	-0.22	-0.92 - 0.48	.531
<u>Co-variates</u>			
Baseline insomnia symptoms	-0.24	-0.71 - 0.23	.316
Baseline experiences of hallucinations		0.64 - 2.49	.001
Age	-0.06		.017
Psychotic experiences – Cognitive disorgan	nization		
DV: Cognitive disorganization			
	β	95% CI	p-value
Group [reference: Control]			1
Intervention	-0.37	-0.84 - 0.11	.130
<u>Co-variates</u>	0.17	-0.440.10	214
Baseline insomnia symptoms Baseline cognitive disorganization	-0.17	-0.440.10 0.59 - 1.05	.214 < .001
Age	-0.02	-0.140.03	< .001 .004
ngu	-0.07	-0.140.05	.004
Positive mental health			
DV: Positive mental health			
	β	95% CI	p-value
Group [reference: Control]			
Intervention	0.07	-1.17 – 1.30	.916
Time [reference: Mid-intervention]	1 10	0.20 1.00	004
End of intervention Group x time interaction	1.18	0.38 – 1.98	.004
Group & time interaction			

Intervention x end of intervention	-0.36	-1.48 - 0.76	.525
Co-variates			
Baseline insomnia symptoms	0.35	-0.18 - 0.88	.202
Baseline positive mental health	4.78	4.21 - 5.34	<.001
Age	-0.01	-0.15 - 0.13	.881
Perceived stress			
DV: Perceived stress			
	β	95% CI	p-value
Group [reference: Control]			
Intervention	-2.03	-3.830.23	.027
Time [reference: Mid-intervention)			
End of intervention	-2.19	-3.560.81	.002
Group x time interaction			
Intervention x end of intervention	1.30	-0.43 - 3.03	.140
Co-variates			
Baseline insomnia symptoms	-0.86	-1.89 - 0.17	.101
Baseline perceived stress	4.79	3.96 - 5.62	<.001
Age	-0.09	-0.26 - 0.09	.326
<u> </u>	0.07	0.20 0.07	1020

Note. CI = Confidence interval

For the effect of group, the co-efficient indicates change in DV score across time in the intervention group *compared* to the control group. For the effect of time, coefficients indicate change in DV score at end of intervention and 6-month follow *compared* to the mid-intervention. For the group x time interaction, the control group and mid-intervention time points are used as the references. For ADHD symptoms, experiences of paranoia, experiences of hallucinations and cognitive disorganization, no time or group x time as measure was not assessed at mid-intervention.

Predictor variables	Model		
	information		
DV: insomnia symptoms at end of treatment	momuton		
Anxiety symptoms			
	β	95% CI	p- value
Group	1.87	0.01 - 3.74	.049
Baseline anxiety symptoms	-0.88	-2.40 - 0.64	.254
Group * baseline anxiety symptoms	0.54	-1.33 - 2.40	.572
Age	0.17	-0.06 - 0.41	.150
Baseline insomnia symptoms	3.85	2.76 - 4.93	<.001
Depression symptoms			
Depression symptoms	0	05% CI	p-
	β	95% CI	value
Group	1.86	-0.02 - 3.75	.054
Baseline depression symptoms	0.09	1.42 - 1.61	.903
Group * baseline depression symptoms	0.08	-1.82 - 1.98	.934
Age	0.02	-0.19 - 0.22	.877
Baseline insomnia symptoms	4.21	3.08 - 5.34	<.001
ADHD symptoms			
	β	95% CI	p- value
Group	1.93	0.06 - 3.80	.043
Baseline ADHD symptoms	0.13	-1.13 - 1.39	.841
Group * baseline ADHD symptoms	1.07	-0.76 - 2.89	.253
Age	0.01	-0.19 - 0.21	.921
Baseline insomnia symptoms	4.27	3.31 - 5.24	<.001
Psychotic experiences - paranoia			
	β	95% CI	p-
Course	-	0.05 2.92	value
Group	1.93 -0.58	0.05 - 3.82 -2.01 - 0.86	.044 .430
Baseline experiences of paranoia Group * baseline experiences of paranoia	-0.38	-2.01 - 0.80 -0.70 - 3.10	.430
Age	0.01	-0.20 - 0.21	.213
Baseline insomnia symptoms	4.15	-0.20 - 0.21 3.12 - 5.18	<.001
Dasenne insonnina symptoms	7.15	5.12 5.10	< .001
Psychotic experiences - hallucinations			
	β	95% CI	p- value
Group	1.96	0.07 - 3.86	.042
Baseline experiences of hallucinations	-0.93	-2.58 - 0.72	.267
Group * baseline experiences of hallucinations	1.14	-0.83 - 3.11	.254
Age	0.01	-0.20 - 0.21	.988

Supplementary Table 3. Regression models for moderators of treatment outcome

<u>r sycholic experiences – cognitive disorganization</u>			
	β	95% CI	p- value
Group	1.94	0.07 - 3.82	.043
Baseline cognitive disorganization	0.79	-0.54 - 2.12	.242
Group * baseline cognitive disorganization	-0.27	-2.13 - 1.59	.778
Age	0.03	-0.17 - 0.23	.774
Baseline insomnia symptoms	4.23	3.26 - 5.19	<.001
Positive mental health			
	0		p-
	β	95% CI	value
Group	1.91	0.02 - 3.81	.048
Baseline positive mental health	0.48	-1.08 - 2.03	.543
Group * positive mental health	-0.25	-2.16 - 1.67	.800
Age	0.01	-0.20 - 0.21	.959
Baseline insomnia symptoms	4.00	2.95 - 5.05	<.001
Perceived stress			
	β	95% CI	p-
	•		value
Group	1.72	-0.15 - 3.59	.070
Baseline perceived stress	-0.53	-1.94 - 0.88	.456
Group * baseline perceived stress	0.59 0.17	-1.25 - 2.44 -0.07 - 0.41	.525 .159
Age Regaling incompio symptoms	4.08	-0.07 - 0.41 3.02 - 5.14	.139 <.001
Baseline insomnia symptoms	4.08	5.02 - 5.14	< .001
Threatening life events			
	β	95% CI	p- value
Group	1.91	0.03 - 3.80	.047
Baseline threatening life events	0.12	-1.10 - 1.33	.849
Group * threatening life events	0.55	-1.30 - 2.39	.561
Age	0.01	-0.19 - 0.22	.896
Baseline insomnia symptoms	4.17	3.17 – 5.17	<.001
Combined moderator			
	β	95% CI	p- value
Group	1.73	-0.17 - 3.62	.074
Combined moderator	-0.61	-2.25 - 1.04	.467
Group * combined moderator	0.97	-1.12 - 3.05	.362
Age	0.18	-0.07 - 0.42	.152
Baseline insomnia symptoms	4.21	3.22 - 5.20	<.001
<i>Note</i> : SCI = Sleep condition indicator. CI = Confidence	re intervals		

Note: SCI = Sleep condition indicator, CI = Confidence intervals

Psychotic experiences - cognitive disorganization

Predictor	1	Model information	n
DV: insomnia symptoms at end of intervention			
Mediator: General sleep quality			
Group predicting insomnia symptoms			
	B	95% CI	p-value
Group Baseline incompie symptome	1.86 4.05	-0.28 - 4.00 2.43 - 5.68	.088 < .001
Baseline insomnia symptoms Baseline general sleep quality	4.03 -0.79	-2.43 - 0.85	< .001 .342
Age	-0.03	-0.23 - 0.17	.742
Group predicting general sleep quality			
	В	95% CI	p-value
Group	-0.30	-0.66 - 0.05	.093
Baseline insomnia symptoms	-0.22	-0.49 - 0.05	.114
Baseline general sleep quality	0.44 -0.22	0.16 - 0.71 - $0.49 - 0.05$.002 .464
Age	-0.22	-0.49 - 0.05	.404
Group and general sleep quality predicting insomnia symptoms			
	В	95% CI	p-value
General sleep quality at end of intervention	-4.73	-5.543.93	<.001
Group	0.43	-0.93 - 1.78	.535
Baseline insomnia symptoms	3.03	2.00 - 4.05	<.001
Baseline general sleep quality	1.27	0.19 - 2.35	.022
Age	0.02	-0.10 - 0.15	.695
Indirect effect	1.43	$-0.12 - 3.24^{1}$	
Mediator: Cognitions about sleep			
Group predicting insomnia symptoms			
<u>Group predicting insomina symptoms</u>	В	95% CI	p-value
Group	1.98	0.21 - 3.75	.029
Baseline insomnia symptoms	4.42	3.43 - 5.40	<.001
Baseline cognitions about sleep	-0.11	-1.09 - 0.87	.823
Age	0.02	-0.17 - 0.21	.833
Group predicting cognitions about sleep	-		
	β	95% CI	p-value
Group Baseling incompie symptoms	-0.53	-0.800.26	<.001
Baseline insomnia symptoms Baseline cognitions about sleep	-0.12 0.54	-0.27 - 0.28 0.39 - 0.68	.110 < .001
Age	-0.01	-0.04 - 0.02	< .001 .583
	-0.01	-0.07 - 0.02	.505

Supplementary Table 5. Bootstrapped mediated regression models for potential mediators of outcome at end of intervention

Group and cognitions about sleep predicting insomnia symptoms			
	β	95% CI	p-va
Cognitions about sleep at end of intervention	-2.67	-3.691.64	<.0
Group	0.57	-1.14 - 2.29	.50
Baseline insomnia symptoms	4.09 1.32	3.18 - 5.00	< .0
Baseline cognitions about sleep Age	-0.01	0.26 - 2.37 - $0.17 - 0.17$.01 .99
Age	-0.01	-0.17 - 0.17	.,,,
Indirect effect	1.41	$0.69 - 2.37^{1}$	
Mediator: Somatic pre-sleep arousal			
Group predicting insomnia symptoms			
	β	95% CI	p-va
Group	2.14	0.39 – 3.89	.01
Baseline insomnia symptoms	4.57	3.56 - 5.57	.79
Baseline somatic pre-sleep arousal	0.15	-0.85 - 1.15	.76
Age	0.03	-0.16 - 0.21	.79
Group predicting somatic pre-sleep arousal	0		
	β	95% CI	p-va
Group	-0.39	-0.65 - 0.12	.0(
Baseline insomnia symptoms Baseline somatic pre-sleep arousal	-0.28 0.41	-0.430.12 0.25 - 0.56	00. 0. >
Age	-0.03	-0.06 - 0.01	0. > 00.
nge	-0.05	-0.00 0.01	.00
Group and somatic pre-sleep arousal predicting insomnia symptoms			
	β	95% CI	p-va
Somatic pre-sleep arousal at end of intervention	-3.11	-4.092.13	<.0
Group	0.94	-0.65 - 2.54	.24
Baseline insomnia symptoms	3.71	2.78 - 4.64). >
Baseline somatic pre-sleep arousal	1.42	0.45 - 2.39	.00
Age	-0.06	-0.23 - 0.11	.49
Indirect effect	1.20	$0.47 - 2.30^{1}$	
Mediator: Cognitive pre-sleep arousal			
Group predicting insomnia symptoms	ρ	050/ CI	
Group	β 1.98	95% CI 0.17 – 3.69	p-va .02
Baseline insomnia symptoms	4.47	0.17 - 5.09 3.41 - 5.54	.02
Baseline cognitive pre-sleep arousal	-0.06	-1.10 - 0.98	.90
Age	0.19	-0.03 - 0.41	.08
Group predicting cognitive pre-sleep arousal			
	β	95% CI	p-va
Group	-0.16	-0.44 - 0.12	.25

-0.24 0.40 -0.01	-0.410.07 0.24 - 0.57 -0.42 - 0.03	.007 < .001 .691
0		
β -3.13 1.47 3.72 1.20 0.17	$\begin{array}{r} 95\% \text{ C1} \\ -4.032.22 \\ -0.01 - 2.96 \\ 2.78 - 4.67 \\ 0.23 - 2.18 \\ -0.02 - 0.36 \end{array}$	p-value < .001 .052 < .001 .016 .082
0.51	$-0.27 - 1.46^{1}$	
β 2.26 3.85 -1.21 0.01	95% CI 0.54 - 3.99 2.81 - 4.89 -2.270.14 -0.18 - 0.19	p-value .011 <.001 .027 .986
B -0.04 -0.09 0.56 -0.01	95% CI -0.32 - 0.23 -0.25 - 0.08 -0.39 - 0.73 -0.04 - 0.02	p-value .770 .311 < .001 .496
β -2.36 2.16 3.65 0.12 -0.02	95% CI -3.351.38 0.56 - 3.77 2.68 - 4.62 -1.02 - 1.25 -0.20 - 0.15	p-value < .001 .009 <.001 .841 .798
0.10	$-0.47 - 0.88^{1}$	
β 1.26 4.71 -0.97 -0.02	95% CI -2.25 - 4.74 2.81 - 6.61 -1.16 - 1.20 -0.39 - 0.35	p-value .475 <.001 .370 .926
	$\beta \\ -3.13 \\ 1.47 \\ 3.72 \\ 1.20 \\ 0.17 \\ 0.51 \\ \beta \\ 2.26 \\ 3.85 \\ -1.21 \\ 0.01 \\ B \\ -0.04 \\ -0.09 \\ 0.56 \\ -0.01 \\ \beta \\ -2.36 \\ 2.16 \\ 3.65 \\ 0.12 \\ -0.02 \\ 0.10 \\ \beta \\ 1.26 \\ 4.71 \\ -0.97 \\ 0.10 \\ \beta \\ 1.26 \\ 4.71 \\ -0.97 \\ 0.10 \\ 0.$	$ \begin{array}{ccccc} \beta & 95\% \ CI \\ -3.13 & -4.032.22 \\ 1.47 & -0.01 - 2.96 \\ 3.72 & 2.78 - 4.67 \\ 1.20 & 0.23 - 2.18 \\ 0.17 & -0.02 - 0.36 \\ \hline 0.51 & -0.27 - 1.46^1 \\ \end{array} $ $ \begin{array}{cccccc} \beta & 95\% \ CI \\ 2.26 & 0.54 - 3.99 \\ 3.85 & 2.81 - 4.89 \\ -1.21 & -2.27 - 0.14 \\ 0.01 & -0.18 - 0.19 \\ \end{array} $ $ \begin{array}{ccccccccccccccccccccccccccccccccccc$

Group predicting chronotype			
	β	95% CI	p-value
Group	-0.12	-0.48 - 0.24	.493
Baseline insomnia symptoms	2.30	-3.64 - 1.57	.706
Baseline chronotype	0.21	-0.01 - 0.44	.058
Age	2.56	-3.52 - 4.04	.892
Group and chronotype predicting insomnia			
symptoms			
	β	95% CI	p-value
Chronotype at end of intervention	1.39	-1.80 - 4.57	.383
Group	1.41	-2.11 - 4.95	.422
Baseline insomnia symptoms	4.66	2.75 - 6.57	<.001
Baseline chronotype	-1.28	-3.57 - 1.02	.267
Age	-0.06	-0.37 - 0.25	.688
Indirect effect	-0.17	$-1.51 - 1.20^{1}$	

Induced effect-0.17-1.51 - 1.20Note. CI = Confidence interval¹ Bias-corrected confidence interval derived from bootstrapping (5000 repetitions)




Figure S1. Change in insomnia symptoms from baseline to the end of the intervention. Dashed lines show the mean change.




Figure S2 Changes in associated variables, moderation, and mediation results at 6-month follow-up. Control group is always used as the reference. **A** – Changes in associated variables: Standardized coefficients and 95% confidence intervals for the effect of group for each associated variable on the change in insomnia symptoms from baseline to 6-month follow-up. **B** – Moderation: Standardized coefficients and 95% confidence intervals for each of the individual group * baseline predictor interactions and the group * combined moderator interaction for each potential moderator of insomnia symptoms at 6-month follow-up. **C** – Mediation: Standardized coefficients and bias-corrected 95% confidence intervals for each potential mediator of insomnia symptoms at 6-month follow-up.